PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 25, 2026Drug Design Development and Therapy0 citationsOpen Access

Beyond Oncogenes: Selectively Targeting Whole-Tumor Cell Growth Regulation

AQAlbert Qin

Key Points

  • This research explores the challenges of oncogene-targeting in cancer therapy and proposes a whole-cell approach.
  • Analyzed the limitations of targeting single oncogenes in drug development
  • Investigated cancer heterogeneity and its impact on treatment
  • Examined mechanisms of drug resistance, including epigenetics and microenvironmental factors
  • Highlighting the potential of targeting whole-cell growth regulation
  • Recommending strategies to differentiate tumor cell networks from normal cells
  • Suggesting improved therapeutic efficacy without compromising safety

Abstract

Abstract: Cell cycle-based surveillance system is an evolutionary adaptation aligned with the complex and heterogeneous nature of cancer in higher-order organisms and serves as a naturally existing model for potent anticancer therapy. It helps provide insights for the reasons underpinning the challenges facing oncogene-targeting in drug development, including cancer heterogeneity, difficulty in identifying “driver” oncogenes, and drug resistance due to additional mutations or other factors such as epigenetic changes, phenotypic adaptation, and microenvironmental influences. This perspective suggests the paradigm shift of targeting the whole cellular process instead of focusing on single-oncogene inhibition. Therefore, a potentially compelling strategy for cancer therapy is to selectively suppress tumor cells via targeting the whole-cell growth regulation while sparing normal cells. Future directions include precisely distinguishing and selectively interfering with tumor cell growth-regulatory networks from those of normally growing cells to achieve maximal clinical efficacy without compromising safety. Keywords: targeted therapy, cell cycle-based anticancer surveillance, cellular growth-regulatory machinery, whole-cell growth regulation, selective anticancer therapy

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Albert Qin (2026) studied this question.

synapsesocial.com/papers/699e919cf5123be5ed04f35bhttps://doi.org/10.2147/dddt.s574224
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A plain language summary about a cell cycle-based, new surveillance mechanism against cancer2024 · 10 citations
  2. 2Caenorhabditis elegans RIG-I-like receptor DRH-1 signals via CARDs to activate antiviral immunity in intestinal cells2024 · 28 citations
  3. 3Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance2025 · 117 citations
  4. 4Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers2017 · 141 citations
  5. 5The Jak-STAT signaling pathway is required but not sufficient for the antiviral response of drosophila2005 · 656 citations